Orchestra Biomed Holdings Inc (OBIO) FinancialsOBIOOrchestra Biomed Holdings Inc

Evaluating the bottom line, Orchestra Biomed Holdings Inc maintains a gross margin of 71.59%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -25404.55%, while the net margin is -26994.32%. These profitability ratios, combined with a Return on Equity (ROE) of -607.32%, provide a clear picture of how effectively OBIO converts its operational activities into shareholder value.

In the context of the broader market, OBIO competes directly with industry leaders such as SMTI and RCEL. With a market capitalization of $265.06M, it holds a significant position in the sector. When comparing efficiency, OBIO's gross margin of 71.59% stands against SMTI's 90.76% and RCEL's 82.17%. Such benchmarking helps identify whether Orchestra Biomed Holdings Inc is trading at a premium or discount relative to its financial performance.

The company reported a gross margin of 71.59% in Q2 2026, indicating strong profitability on sales despite overall losses. The total revenue for Q2 2026 was $88,000, down from previous quarters, highlighting revenue challenges.